HTG Molecular Diagnostics, Inc. (HTGM) Downgraded by ValuEngine to Strong Sell

ValuEngine downgraded shares of HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) from a sell rating to a strong sell rating in a report issued on Tuesday.

HTGM has been the subject of a number of other research reports. HC Wainwright reiterated a buy rating and set a $6.00 price objective on shares of HTG Molecular Diagnostics in a research note on Thursday, June 29th. Zacks Investment Research upgraded HTG Molecular Diagnostics from a sell rating to a hold rating in a research note on Tuesday, July 18th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating to the company’s stock. The company presently has an average rating of Hold and an average target price of $6.17.

Shares of HTG Molecular Diagnostics (NASDAQ HTGM) opened at 1.89 on Tuesday. The company’s 50-day moving average price is $1.84 and its 200 day moving average price is $1.84. The company’s market cap is $21.64 million. HTG Molecular Diagnostics has a one year low of $1.20 and a one year high of $4.45.

HTG Molecular Diagnostics (NASDAQ:HTGM) last released its earnings results on Tuesday, August 8th. The medical research company reported ($0.60) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.60). The firm had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $1.80 million. On average, equities research analysts anticipate that HTG Molecular Diagnostics will post ($2.29) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece was published by Markets Daily and is owned by of Markets Daily. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.themarketsdaily.com/2017/10/11/htg-molecular-diagnostics-inc-htgm-downgraded-by-valuengine-to-strong-sell.html.

In other HTG Molecular Diagnostics news, major shareholder Holdings A/S Novo sold 1,149,813 shares of HTG Molecular Diagnostics stock in a transaction on Friday, August 25th. The stock was sold at an average price of $1.81, for a total transaction of $2,081,161.53. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 1,659,998 shares of company stock valued at $3,073,696 in the last quarter. 7.60% of the stock is owned by company insiders.

Large investors have recently made changes to their positions in the business. UBS Group AG purchased a new position in HTG Molecular Diagnostics during the first quarter valued at $137,000. Two Sigma Securities LLC purchased a new position in HTG Molecular Diagnostics during the first quarter valued at $150,000. Granahan Investment Management Inc. MA purchased a new position in HTG Molecular Diagnostics during the first quarter valued at $228,000. Finally, Vanguard Group Inc. raised its stake in HTG Molecular Diagnostics by 38.9% during the second quarter. Vanguard Group Inc. now owns 135,234 shares of the medical research company’s stock valued at $359,000 after buying an additional 37,841 shares during the last quarter. Institutional investors and hedge funds own 21.67% of the company’s stock.

HTG Molecular Diagnostics Company Profile

HTG Molecular Diagnostics, Inc is a commercial-stage company that develops and markets a technology platform to facilitate the routine use of complex molecular profiling. The Company’s HTG Edge and HTG EdgeSeq platforms, consisting of instrumentation, consumables and software analytics, are used in sample profiling applications, including tumor profiling, molecular diagnostic testing and biomarker development.

Receive News & Ratings for HTG Molecular Diagnostics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HTG Molecular Diagnostics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply